DAPT Study
  |  Contact  

AboutFor PatientsFor CliniciansFor Media
DAPT Score Calculator
Patient Characteristics
Diabetes Mellitus
Cigarette Smoking Within Last Two Years
Prior Myocardial Infarction or Percutaneous Coronary Intervention
History of Congestive Heart Failure or Left Ventricular Ejection Fraction < 30%
Index Procedure Characteristics
Myocardial Infarction at Presentation
Stenting of Vein of Graft
Stent Diameter < 3mm

The DAPT Score was developed to predict combined ischemic and bleeding risk for patients being considered for continued thienopyridine therapy in addition to aspirin beyond 1 year after coronary stent treatment. The Score was developed from the DAPT Study randomized trial data, in which patients were randomized to continued thienopyridine therapy (clopidogrel or prasugrel) vs. placebo. Patients were randomized only if they had not sustained a heart attack, stent thrombosis, stroke, repeat revascularization, or bleed, and had been adherent with medications during the first year. Patients receiving oral anticoagulation or with limited life expectancy were excluded.* Outcomes are shown according to DAPT Score limited to patients not receiving a paclitaxel-eluting stent, since such stents are no longer commonly used in clinical practice.

Mauri et al., NEJM 2014.

Yeh et al., JAMA 2016.